1. paul0g7G
2. JimmyMcGill
3. 007Bondsman
4. BUYtheWeak
5. jerryff
1.JimmyMcGill 09/24/2017
Buy Out talk from the past
2.paul0g7G 10/05/2017
Dementia-related psychosis
3.BUYtheWeak 10/05/2017
This is not the first time the FDA has granted Nuplazid "breakthrough therapy" status. It did so in 2014 in the PDP indication. $60.00+ before eoy.
4.jerryff 01/19/2018
What’s the average Price Target for this?
5.007Bondsman 09/24/2017
Been in and out the last year. Anything else worth staying here for if no BO talk?
6.JimmyMcGill 07/09/2018
Cautious piece from Sirf Online
7.JimmyMcGill 10/05/2017
Over $40 opening?
8.paul0g7G 09/29/2017
Rounding out
9.jerryff 04/10/2018
Acadia Pharmaceuticals (ACAD): Another Glimpse Into Nuplazid Safety Profile
10.paul0g7G 02/28/2018
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW